Contributions of Clinical Obesity and Preclinical Obesity to the All-Cause Mortality Risk: Findings From the UK Biobank Cohort

IF 6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes/Metabolism Research and Reviews Pub Date : 2025-10-16 DOI:10.1002/dmrr.70095

Manrong Xu, Menghan Li, Yawen Zhang, Lianxi Li, Yun Shen, Gang Hu

{"title":"Contributions of Clinical Obesity and Preclinical Obesity to the All-Cause Mortality Risk: Findings From the UK Biobank Cohort","authors":"Manrong Xu, Menghan Li, Yawen Zhang, Lianxi Li, Yun Shen, Gang Hu","doi":"10.1002/dmrr.70095","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The definition of clinical obesity was newly announced. The aim of our study was to investigate the association of preclinical obesity and clinical obesity either at baseline or determined during follow-ups with the risk of all-cause mortality.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data were collected from 232,721 participants in the UK Biobank. Dysfunctions caused by obesity, in combination with an excess of anthropometric parameters, were used to diagnose clinical obesity. Participants were categorised into six clusters according to their baseline and follow-up dysfunction status. Time-dependent Cox proportional hazards regression was used to compare hazard ratios (HRs) for mortality across six clusters.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In a total of 19,704 deaths over a mean follow-up of 13.4 years, participants in Cluster 6 (clinical obesity at baseline; HR = 2.30, 95% CI: 2.16–2.44) and Cluster 3 (non-obesity with baseline dysfunctions; HR = 2.02, 95% CI: 1.85–2.20) exhibited the highest multivariable-adjusted mortality risk compared with participants without obesity and dysfunction at baseline and during follow-up (Cluster 1). This was followed by participants in Cluster 2 (non-obesity without baseline but with follow-up dysfunctions; HR = 1.99, 95% CI: 1.88–2.10), Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 1.97, 95% CI: 1.87–2.07), and Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 1.15, 95% CI: 1.09–1.22). Subgroup analyses showed consistently higher mortality risks in Cluster 6 across various demographics, notably among individuals with higher educational qualifications.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Clinical obesity was significantly associated with elevated all-cause mortality risk. These findings underscore the importance of early screening and intervention for dysfunctions in patients with obesity.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 7","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70095","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The definition of clinical obesity was newly announced. The aim of our study was to investigate the association of preclinical obesity and clinical obesity either at baseline or determined during follow-ups with the risk of all-cause mortality.

Methods

Data were collected from 232,721 participants in the UK Biobank. Dysfunctions caused by obesity, in combination with an excess of anthropometric parameters, were used to diagnose clinical obesity. Participants were categorised into six clusters according to their baseline and follow-up dysfunction status. Time-dependent Cox proportional hazards regression was used to compare hazard ratios (HRs) for mortality across six clusters.

Results

In a total of 19,704 deaths over a mean follow-up of 13.4 years, participants in Cluster 6 (clinical obesity at baseline; HR = 2.30, 95% CI: 2.16–2.44) and Cluster 3 (non-obesity with baseline dysfunctions; HR = 2.02, 95% CI: 1.85–2.20) exhibited the highest multivariable-adjusted mortality risk compared with participants without obesity and dysfunction at baseline and during follow-up (Cluster 1). This was followed by participants in Cluster 2 (non-obesity without baseline but with follow-up dysfunctions; HR = 1.99, 95% CI: 1.88–2.10), Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 1.97, 95% CI: 1.87–2.07), and Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 1.15, 95% CI: 1.09–1.22). Subgroup analyses showed consistently higher mortality risks in Cluster 6 across various demographics, notably among individuals with higher educational qualifications.

Conclusions

Clinical obesity was significantly associated with elevated all-cause mortality risk. These findings underscore the importance of early screening and intervention for dysfunctions in patients with obesity.

Abstract Image

查看原文本刊更多论文

临床肥胖和临床前肥胖对全因死亡风险的贡献：来自英国生物银行队列的发现。

背景：临床肥胖的定义是新近公布的。本研究的目的是调查临床前肥胖和临床肥胖在基线或随访期间与全因死亡率风险的关系。方法：数据来自英国生物银行的232,721名参与者。由肥胖引起的功能障碍，结合过量的人体测量参数，被用来诊断临床肥胖。参与者根据他们的基线和随访功能障碍状态分为六组。时间相关Cox比例风险回归用于比较六个聚类的死亡率风险比（hr）。结果：在平均13.4年的随访中，共有19,704例死亡，第6类（基线时临床肥胖；HR = 2.30, 95% CI: 2.16-2.44）和第3类（非肥胖伴基线功能障碍；HR = 2.02, 95% CI: 1.85-2.20）的参与者与基线和随访期间无肥胖伴功能障碍的参与者（Cluster 1）相比，显示出最高的多变量调整死亡风险。随后是第2组（无基线的非肥胖但有随访功能障碍；HR = 1.99, 95% CI: 1.88-2.10）、第5组（临床前肥胖伴随访功能障碍；HR = 1.97, 95% CI: 1.87-2.07）和第4组（临床前肥胖伴随访功能障碍；HR = 1.15, 95% CI: 1.09-1.22）的参与者。亚组分析显示，在不同的人口统计数据中，第6类人群的死亡率风险始终较高，特别是在教育程度较高的人群中。结论：临床肥胖与全因死亡风险升高显著相关。这些发现强调了早期筛查和干预肥胖患者功能障碍的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢

CiteScore

17.20

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.